| Ticker: QGENF | Johannes Vermeerplen 9-1 | |
| Exchange: NASDAQ-National Market | Amsterdam, Foreign 1071 DV | |
| Industry: Manufacturing | 0206645500 |
| Type of Shares: | Common Shares | Filing Date: | ||
| U.S. Shares: | 2,345,000 | Offer Date: | 6/27/96 | |
| Non-U.S. Shares: | 1,005,000 | Filing Range: | $11.00 - $13.00 | |
| Primary Shares: | 2,514,000 | Offer Price: | $12.00 | |
| Secondary Shares: | 836,000 | Gross Spread: | $0.84 | |
| Offering Amount: | $40,200,000 | Selling: | $0.42 | |
| Expenses: | $1,798,320 | Reallowance: | $0.10 | |
| Shares Out After: | 16,224,000 |
| Manager | Tier | Phone |
| Goldman, Sachs & Co. | Lead Manager | (212) 902-1172 |
| Alex. Brown & Sons Incorporated | Co-manager | (410) 727-1700 |
| Montgomery Securities | Co-manager | 4156272220 |
| Auditor: Arthur Andersen | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $36.99 | $12.48 | $7.89 | Assets: | $27.41 |
| Net Income: | $2.40 | $0.96 | $0.31 | Liabilities: | $14.34 |
| EPS: | $0.18 | $0.07 | $0.02 | Equity: | $13.06 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is a provider of technology used in the separation and purification of nucleic acids. Nucleic acids also known as DNA and RNA, are the fundamental regulatory molecules of life. Since 1986 the Company has developed and marketed a broad range of proprietary products for the academic and industrial research market. More recently, the increased understanding of nuclei acid structure and function combined with the development of innovative technologies such as Polymerase Chain Reaction has resulted in a rapid expansion in the potential uses of nucleic acids beyond the research market into developing commercial markets. The Company believes that by targeting its enabling nucleic acid separation and purification technologies to numerous participants in each of these developing commercial markets, it will optimize and diversify its opportunities for growth. QIAGEN has experienced significant growth in the past, and since 1993 has had a compound annual growth of approximately 50% in net sales and 82% in net income. |
| Use of Proceeds |
| Proceeds from the offering will be used to build a manufacturing and research facility in the U.S. and expand existing facilities in Europe. The rest of the proceeds will be devoted to increased research, marketing and distribution efforts, building information systems and general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.